School of Chinese Medicine
Cathepsin K (CatK) is one of the most potent proteases in lysosomal cysteine proteases family, of which main function is to mediate bone resorption. Currently, CatK is among the most attractive targets for anti-osteoporosis drug development. Although many pharmaceutical companies are working on the development of selective inhibitors for CatK, there is no FDA approved drug till now. Odanacatib (ODN) developed by Merck & Co. is the only CatK inhibitor candidate which demonstrated high therapeutic efficacy in patients with postmenopausal osteoporosis in Phase III clinical trials. Unfortunately, the development of ODN was finally terminated due to the cardio-cerebrovascular adverse effects. Therefore, it arouses concerns on the undesirable CatK inhibition in non-bone sites. It is known that CatK has far-reaching actions throughout various organs besides bone. Many studies have also demonstrated the involvement of CatK in various diseases beyond the musculoskeletal system. This review not only summarized the functional roles of CatK in bone and beyond bone, but also discussed the potential relevance of the CatK action beyond bone to the adverse effects of inhibiting CatK in non-bone sites.
Cathepsin K, osteoclast, bone resorption, osteoporosis, osteoarthritis, Cathepsin K inhibitor, cardiovascular diseases, lung fibrosis
Source Publication Title
Frontiers in Cell and Developmental Biology
Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.
Link to Publisher's Edition
Dai, R., Wu, Z., Chu, H., Lu, J., Lyu, A., Liu, J., & Zhang, G. (2020). Cathepsin K: The Action in and Beyond Bone. Frontiers in Cell and Developmental Biology, 8. https://doi.org/10.3389/fcell.2020.00433